AUTHORS
Xiaohong Zhao, MD, PhD, Mark B. Meads, PhD2, Rafael Renatino Canevarolo, PhD3, Praneeth Reddy Sudalagunta, PhD4, Daniel Deavila, MS5, Pompom Ghosh, PhD6, chaomei Zhang7, Maria C. Silva8, Angel Perez9, Kinga M. Cid10, Ryan F. Gebert11, Gabriel DeAvila12, Bailey J. Spence13, Samer S. Sansil14, Sean Yoder15, Francesco Maura, MD16, Ciara Louise L Freeman, MD, PhD17, Doris K. Hansen, MD18, Melissa Alsina, MD19, Rachid Baz, MD20, Ariosto Siqueira Silva, PhD21, Kenneth H. Shain, MD, PhD22, Xiaofei Song, PhD23
AFFILIATIONS
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States, Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
15 Moffitt Cancer Center, Tampa, Florida, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Moffitt Cancer Center, Tampa, Florida, United States
18 Moffitt Cancer Center, Tampa, Florida, United States
19 Moffitt Cancer Center, Tampa, Florida, United States
20 Moffitt Cancer Center, Tampa, Florida, United States
21 Moffitt Cancer Center, Tampa, Florida, United States
22 Moffitt Cancer Center, Tampa, Florida, United States
23 Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Background
Despite high initial response rates to BCMA CAR-T therapy in relapsed multiple myeloma (MM), some patients do not achieve durable responses. Prior genomic studies and small scRNAseq cohorts have suggested that tumors may escape BCMA-directed immune pressure due to high genomic complexity and plasma cell (PC) identity escape, but the epigenetic mechanisms have yet to be examined.
Methods
CD138+ cells were purified from bone marrow aspirates (BM) of 22 MM patients prior to CAR-T therapy (ciltacabtagene autoleucel) and cDNA libraries built for sequencing using scMultiome kits (10x Genomics, scRNAseq+scATACseq). Patients were stratified by response, 13 had VGPR-or-better (R) and 9 had less-than-VGPR (NR). A subset of these also had a paired BM biopsy at progression. Malignant PCs were identified via CellTypist combined with inferCNV compared to healthy donors; tumor subclones were identified by inferCNV. Differentially expressed genes (DEGs, R vs. NR) were identified and gene set enrichment analysis (GSEA) was performed against a set of 400 genesets (MSigDB). Gene regulatory networks (eRegulons) linked to tumor cell states were inferred by integrating chromatin accessibility and gene expression using SCENIC+. Longitudinal clonal phylogeny was assessed with Numbat.
Results
GSEA analysis of preCART PCs revealed increased PC identity signatures and reduced KRAS signaling are enriched in R. In contrast, gene sets enriched in NR patients indicated high biosynthetic, proliferative, and metabolic activity: translation, MYC and E2F transcription, oxidative phosphorylation, mTORC1 signaling, and proteasome activity. DEGs complimented pathway analysis with increased expression of mitochondrial and proliferation genes in NR; and PC differentiation and quiescence genes in R. PC pathways in R were similar to those found in dynamic tumor subclones (3-5 per tumor) that contracted (C) at progression in 5 tumors with follow-up, and C subclones also expressed higher levels of PC surface markers like TNFRSF17, SDC1, and CD38.
Differential ATAC-seq analysis corroborated this axis: peaks more accessible in R cells localized near PBX1 motifs, implicated in normal PC differentiation. While peaks more accessible in NR cells were enriched near anabolic/translation (PHGDH) and BCR regulation (PTPN22, VAV3) genes. TF motif enrichment further distinguished the two populations at the regulatory level. R DA chromatin was enriched with motifs associated with PC biology and regulation of ER stress pathways (bHLH, SNAI1). NR DA chromatin instead was dominated by RUNX family (RUNX1/2/3) and interferon-responsive motifs (STAT2, IRF3, IRF8, STAT1:STAT2), suggesting an increased proliferative capacity, stress adaptation, and interferon/inflammatory transcriptional programs. Enhancer-driven gene regulatory networks (eRegulons) were characterized by aligning gene expression with open chromatin, showing increased UPR (ATF6) and regulation of PC identity (PRDM1, POU2F2, BACH1, ZBTB20) regulons in R. In contrast, NR eRegulons suggest a stress-adapted, prosurvival, dysdifferentiated (IRF4, ATF4, KLF13, JUNB) PC state.
Reconstruction of clonal phylogeny in 5 patients with a follow-up progression sample revealed that genomic complexity correlates with poorer best response. R patients harbored predominantly monoclonal or minimally branched malignant PC populations, with low total CNV burden and at most a single subclonal split. In contrast, NR patients had multi-branch phylogenies with 3-5 genetically distinct subclones with progressively acquired CNV events, indicating substantial pre-existing intratumoral heterogeneity. These findings suggest that resistance to CART therapy is associated with distinct transcriptional/chromatin programs and greater clonal diversity.
Conclusion
Tumor regulatory axes, phenotypes, and clonal dynamics distinguishing CAR-T response in MM were identified by linking combined single cell gene expression and open chromatin architecture with TF regulons: R tumors display a quiescent, more terminally differentiated PC state and more limited clonal populations, while NR tumors exhibit a more dynamic and metabolic state, arising from genomically heterogeneous, multi-clonal architecture. Together, these findings support a model in which resistant MM cells remain plasma cells but have undergone subclonal transcriptional rewiring toward a stress-adapted survival state, while sensitive cells retain a homeostatic secretory plasma cell program.
DISCLOSURES
Xiaohong Zhao, MD, PhD: No relevant conflicts of interest to declare.